UK quoted biotech performance and investor base in 2021 (June update)
This report is an exclusive analysis of the performance of the UK-quoted biotech sector and the breadth of its investor base by Radnor Capital Partners on behalf of the BIA.
Given the remarkable outperformance of the sector during 2020, it is fantastic to see that much of this outperformance has been maintained through 2021 so far. Since the start of the pandemic (March 2020) the Unweighted Broad Biotech Index has outperformed the FTSE All Share by +190%. Since our last review in January 2021, the sector has outperformed by +13%. We continue to see strong demand from North American investors for UK-quoted biotech (net inflow of £723m) and European investors (net inflow of £130m). Whereas UK larger institutions continued to be material net sellers in value terms with an outflow of £231m.